Research finds no advantages in 4-drug regimen for HIV patients

Adding a fourth drug to the existing three-drug anti-retroviral treatment for the initial stages of HIV-1 has not shown any benefits, according to a U.S. study that covered some 765 patients for three years.
Posted : Mon, 14 Aug 2006 11:04:00 GMT
By : Ryan Jones
Category : Health
News Alerts by Email ( click here )
Health News | Home
NEW YORK: Adding a fourth drug to the existing three-drug anti-retroviral treatment for the initial stages of HIV-1 has not shown any benefits, according to a U.S. study that covered some 765 patients for three years.

Researchers from the Medical College of Cornell University said in an article published in the latest issue of the Journal of the American Medical Association that there were no significant differences over three years between the standard 3-drug regimen and a new 4-drug regimen.

Dr Roy Gulick, who led the team, said, "High rates of virologic suppression achieved in this study support current guidelines that recommend two nucleosides plus efavirenz among preferred regimens for the initial treatment of HIV-1 infection.

Adding abacavir as a fourth drug to the standard initial 3-drug regimen did not change toxicity or adherence but provided no additional benefit.

The 3-drug regimen has been found to suppress presence of HIV in blood, increase CD4 immune cells, delay clinical progression and improve survival.

Some researchers had suggested adding more drugs to the regimen in order to improve anti-retroviral activity, but the study has now established it has no advantages. Instead, the researchers found, it could cause virologic failure, adverse events or drug resistance. Besides, it will add to the costs of an already overburdened system.

The study, supported by the National Institutes of Health, was conducted at more than 40 U.S. sites. More than half the patients in the study were black or Hispanic and almost 20 per cent were female. The patients were randomly assigned to one of two regimens: the four-drug cocktail (zidovudine, lamivudine and abacavir and the non-nucleoside drug efavirenz), or a three-drug cocktail (containing zidovudine, lamivudine and efavirenz).

About the same number of patients in both groups (88 per cent of the four-drug group and 85 per cent of the three-drug group) achieved undetectable blood levels of HIV. After a median three-year follow-up, 25 per cent of the four-drug group and 26 per cent of the three-drug group reached virologic failure, meaning the drugs could no longer reduce the levels of virus in the patient's blood.

In the past 25 years, AIDS has caused 25 million deaths worldwide and 40 million people are living with the HIV virus. It has been established that prognosis is much better for people who can get the powerful new drugs. However, current drugs do not cure AIDS or prevent people from spreading it.

Copyright, respective author or news agency

Share/Save/Bookmark

Article : Research finds no advantages in 4-drug regimen for HIV patients
Print this article
Email this article

Stay Updated
News gadget on your Google homepage
Subscribe to a news feed in Google Reader


Related News



    Have your Say
    Name
    Email
    Subject
    Your Comment

    Enter Verification code
     
      


     
    Your Comments

    GREETING
    By: Abdul , Thu, 18 Jan 2007 21:03:26 GMT

    very good work, kindly e-mail me any thing concer HIV/AIDS, MALARIA.


    Other interesting articles
    By: Katie , Sun, 17 Dec 2006 05:40:40 GMT

    I found this article to be very eye opening
    www.healthmad.com/Conditions-and-Diseases/Aids-in-America.11071



    More Health News click here
    Follow The Earth Times
    Subscribe to RSS Follow Earth Times on TwitterNews by email
    Share/Save/Bookmark

     
     



     
    Subscribe to free Earthtimes
    News Alerts by Email Click here
    For RSS Feeds Click here
    or Create your own RSS

    Add to Google Toolbar
    Breaking News
    Press Releases

     
     
    Medical College of Cornell University

     

    The Earth Times
    News Category

    © 2010 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
    Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.